> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Trails Edge Capital Takes A 5.2% Passive Stake In Avalo Therapeutics
- URL: https://www.bullished.co/trails-edge-capital-takes-a-5-2-passive-stake-in-avalo-therapeutics-9e5d7c8e/
- Published: 2026-10-29T20:43:46.000Z
- Updated: 2026-11-05T19:41:18.000Z
- Description: The Atlanta manager and its Cayman fund hold 2,803,761 Avalo shares and certify they are not seeking control.
- Author: Matteo Parrino
- Tags: SEC Filings, AVTX, Industry: Healthcare

Trails Edge Capital Partners, an Atlanta investment manager, and its Cayman Islands fund hold [2,803,761 shares](https://www.sec.gov/Archives/edgar/data/0002077247/000149315226049273/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of Avalo Therapeutics, or 5.2% of the company, according to a Schedule 13G filed Thursday. The filers certify they did not buy the stock to change or influence control of Avalo.

## One fund, three filers

All of the shares are held directly by Trails Edge Biotechnology Master Fund, LP, a Cayman Islands partnership. Trails Edge Capital Partners, LP, a Delaware partnership, is the fund's investment manager, and Ortav Yehudai is its Chief Investment Officer.

Yehudai exercises voting and investment discretion over the shares, the filing says. Each of the three filers may therefore be deemed to beneficially own the same stake as of the October 22, 2026 event date, and each reports sole voting power over [all 2,803,761 shares](https://www.sec.gov/Archives/edgar/data/0002077247/000149315226049273/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co), with none shared.

The 5.2% is measured against 53,629,989 Avalo shares outstanding as of August 3, 2026, the count the company gave in its quarterly report filed August 6, 2026\. The filers are not summing separate positions: the same block is reported on each cover page.

## A passive-investor certification

A 13G is the passive ownership disclosure, as opposed to the activist version. In signing it, the filers certified that the shares were not acquired and are not held to affect control of the issuer, other than activities tied to a director nomination under a specific SEC rule.

Avalo, based in Wayne, Pennsylvania, is a clinical-stage biotechnology company developing treatments for immune-mediated inflammatory diseases, focused on drugs that block a protein called IL-1β. Its lead candidate, abdakibart, is an antibody in a mid-stage trial in hidradenitis suppurativa, a chronic inflammatory skin disease. That trial covers approximately 250 adults with moderate to severe disease, according to the company's 10-K for 2025.

Avalo has no approved products and relies on outside contract manufacturers. It holds a worldwide exclusive license to abdakibart from Eli Lilly. The company's market value was about $382 million in Thursday trading.

The filers' 2,803,761 shares sit on the same 53,629,989-share base Avalo reported in August.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — Trails Edge Capital Partners, LP re: Avalo Therapeutics, Inc. (AVTX)](https://www.sec.gov/Archives/edgar/data/0002077247/000149315226049273/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR